Generex Biotechnology Corp  (GNBT) Trade Now »     Rate GNBT  -  Discuss GNBT  -  Add to Watch List        

As a diabetic and as a former co-manager for an offshore private wealth fund, I have long-followed the diabetic drug market, the large pharmas, and the small-cap biotech companies in that space. <!--more-->The global diabetes market affects approximately 246 million people worldwide and this number is increasing. The World Health Organization projects that diabetics will increase to 300 million by 2011. And, the International Diabetes Federation predicts 380 million diabetics by 2025.

With Pfizer dropping Exubra, Generex's Oral-lyn has very little competition in the non-injectable insulin delivery market. India is now on board with Oral-lyn and 5 other countries are expected to approve it by year's end. This will bring much needed revenue beginning early next year. Generex is also expecting positive news on its cancer vaccines by end of '07 (Antigen Express).